Apogee Therapeutics, Inc. Common Stock
Compare this stock
APGE Stock Report Card
$
65%
Performance
Score:
28/100
APGE returned -16.93% in the last 12 months. Based on SPY's performance of -13.93%, its performance is below average giving it a score of 28 of 100.
Earnings
Score:
100/100
APGE has missed earnings 1 times in the last 20 quarters.
Volatility
Score:
44/100
APGE has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
Apogee Therapeutics, Inc. Common Stock Summary
Nasdaq / APGE
Healthcare
Biotechnology
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
APGE scored highly on our reportcard. Here are some similar companies and how they performed.
